1. Home
  2. GRNT vs COLL Comparison

GRNT vs COLL Comparison

Compare GRNT & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Granite Ridge Resources Inc.

GRNT

Granite Ridge Resources Inc.

N/A

Current Price

$6.34

Market Cap

667.4M

Sector

Finance

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

N/A

Current Price

$25.37

Market Cap

752.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRNT
COLL
Founded
2013
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
667.4M
752.3M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
GRNT
COLL
Price
$6.34
$25.37
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$8.60
★ $44.00
AVG Volume (30 Days)
★ 1.5M
581.3K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 6.98%
N/A
EPS Growth
★ 28.57
N/A
EPS
N/A
★ 0.64
Revenue
$450,306,000.00
★ $780,567,000.00
Revenue This Year
$51.35
$6.59
Revenue Next Year
$6.79
$1.89
P/E Ratio
★ N/A
$39.55
Revenue Growth
★ 18.49
N/A
52 Week Low
$4.18
$21.43
52 Week High
$6.54
$50.79

Technical Indicators

Market Signals
Indicator
GRNT
COLL
Relative Strength Index (RSI) 66.62 64.44
Support Level $4.67 $21.67
Resistance Level N/A $26.39
Average True Range (ATR) 0.33 0.86
MACD 0.09 0.18
Stochastic Oscillator 90.98 72.48

Price Performance

Historical Comparison
GRNT
COLL

About GRNT Granite Ridge Resources Inc.

Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: